Incidence and severity of trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis are variable among different malignancies.

Toni Choueiri outlines the results of the phase 3 KEYNOTE-564 trial showing the benefit of adjuvant treatment with pembrolizumab in patients with high-risk renal cell carcinoma.

Ingrid Mayer discusses findings from the ECOG-ACRIN EA1131 trial showing no benefit of postoperative platinum-based chemotherapy versus capecitabine in patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy.

At 1 year, OS rates were a comparable 85.41% in the rheumatic disease group and 87.59% in the control group for locoregional disease; the corresponding rates for distant disease were 44.05% and 58.44%.

Findings from an open-label phase 2 study suggest the first-in-class HIF-2α inhibitor MK-6482 has “promising efficacy and tolerability” in the treatment of renal cell carcinoma associated with von Hippel–Lindau disease.

Research suggests that women who use hormone-modulating breast cancer treatments such as tamoxifen or aromatase inhibitors may experience a reduced risk for neurodegenerative disease.

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

No other factor investigated was found to significantly predict hyperprogressive disease.

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

The study included data on 405,878 individuals who participated in a standardized medical screening program in Taiwan between 1996 and 2007, which involved testing for diabetes, pulmonary disease, and markers of cardiovascular disease (blood pressure, total cholesterol, and heart rate), chronic kidney disease (proteinuria and glomerular filtration rate), and gouty arthritis (uric acid).